Jefferies provided color on Becton, Dickinson and Co. BDX. In a research report published today, Jefferies stressed strong performances of the company's Biosciences and Diagnostics units as the driver of the company's revenues.
In the report, Jefferies states, "The outlook for both its Biosciences and Diagnostics units, which collectively account for
nearly 50% of composite revenue, are amongst the brightest in BDX's portfolio, owing to a
rash of significant new product introductions. Such new product launches should have the
effect of stimulating BDX's composite organic revenue growth trajectory back above the 6%-
range, in our view, which could represent a key multiple expansion catalyst."
At the moment, Jefferies has a Buy rating and a price target of $98 placed on the company's stock.
On Monday, Becton lost 0.64% of its value to close the day at $85.21.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst RatingsBecton Dickinson and Co.Health CareHealth Care EquipmentJefferies
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in